Lytix Biopharma appoints new Chairman of the Board

19 Apr 2023 08:01 CEST

Oslo, Norway, April 18, 2023 – Lytix Biopharma AS (“Lytix”) (Euronext Growth
Oslo: LYTIX), a clinical stage immuno-oncology company, announces the election
of a new Chairman of the Board at today’s General Assembly. The new Chairman is
Dr Marie Roskrow, a senior executive with international experience in both
lifesciences and investment banking. She holds a medical degree and a PhD in
Immunology and serves currently as the Chairman of a number of international
biotechnology companies.


“I’m very excited that Marie Roskrow is joining Lytix as the new Chairman of our
board. Marie has a very strong and relevant background within immune oncology
and the finance sector, and I look forward to collaborating with her on further
development and commercialization of our core technology and drug candidates”,
says Øystein Rekdal, CEO of Lytix Biopharma. “I would like to take the
opportunity to thank Gert W. Munthe for his strong support and active
contribution to our board, both as Chairman and a board member over several
years”, Rekdal adds.


In addition to high level clinical and research positions, Dr. Roskrow has
extensive experience as an investment banker, CEO and Chairman in both private
and listed companies, such as the GSF Research Institute (Munich), Patrys Ltd
(Melbourne), Imevax (Munich) and Lazard Healthcare Investment Banker (New York,
San Francisco, Sydney). She has also participated in dozens of public and
private biotechnology and pharmaceutical merger and acquisition deals, company
financings and product in/out-licensing deals.


“I find Lytix Biopharma’s technology very unique and promising and look forward
very much to using my expertise to help bring the company to a commercial
success”, says Dr. Roskrow, as the new Chairman of the Board in Lytix Biopharma.


Lytix’ Board of Directors now consist of:
• Marie Ann Roskrow (Chairman);
• Brynjar Forbergskog;
• Marie-Louise Fjällskog;
• Kjetil Hestdal;
• Evelina Vågesjö; and
• Jayson Rieger.


For more information, please contact:
Gjest Breistein, CFO: gjest.breistein@lytixbiopharma.com
Ole Peter Nordby, Head of IR & Communication Manager:
ole.peter.nordby@lytixbiopharma.com

Lytix in brief:
Based in Oslo, Norway, Lytix Biopharma is a clinical stage immuno-oncology
company developing novel cancer immunotherapies, an area within cancer therapy
that is aimed at activating the patient’s immune system to fight cancer. The
Company’s technology is based on pioneering research in “host defense peptides”
– nature’s first line of defense towards foreign pathogens. Lytix Biopharma’s
lead product, LTX-315, is a first-in-class oncolytic molecule representing a new
and superior in situ therapeutic vaccination principle to boost anti-cancer
immunity, with the potential to be the ideal combination partner with other
types of immunotherapy. LTX-315 target cancer cells and disintegrate their cell
membranes, causing immunogenic cell death and release of a patient’s tumor
specific antigens. This mode of action allows cytotoxic T cells to recognize,
infiltrate, and attack cancer cells. The Company was listed on Euronext Growth
in Oslo in June 2021, following a private placement covered by investors such as
PBM Capital, a US based, healthcare-focused investment firm.

More information:
Access the news on Oslo Bors NewsWeb site